Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters

A method of identifying and treating a subject that has a CNS disease or disorder, comprising:

• assaying a biological sample from the subject;
• detecting the presence of the GG genotype of SNP rs12217173 in the sample;
• identifying the subject as likely to be responsive to treatment with liafensine;
• and,
• administering, to the identified subject, an effective amount of liafensine;
• wherein the CNS disease or disorder is selected from the group consisting of a major depressive disorder (MDD), treatment-resistant depression (TRD), major depression with psychotic feature(s), depression with peri- or postpartum onset, a post-traumatic stress disorder (PTSD), a bipolar disorder, an obsessive-compulsive disorder (OCD), an eating disorder, attention-deficit hyperactivity disorder (ADHD), a sleep disorder, a substance use disorder, Tourette syndrome (TS), schizophrenia, epilepsy, migraine, and an autism spectrum disorder.